Cargando…
Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevale...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678641/ https://www.ncbi.nlm.nih.gov/pubmed/29142978 http://dx.doi.org/10.1016/j.ekir.2017.02.003 |
_version_ | 1783277479661666304 |
---|---|
author | Cai, Qingqing Xie, Xinfang Wang, Jinwei Shi, Sufang Liu, Lijun Chen, Yuqing Lv, Jicheng Zhang, Hong |
author_facet | Cai, Qingqing Xie, Xinfang Wang, Jinwei Shi, Sufang Liu, Lijun Chen, Yuqing Lv, Jicheng Zhang, Hong |
author_sort | Cai, Qingqing |
collection | PubMed |
description | INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. RESULTS: Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07–9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02–1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01–1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96–0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91–1.30; P = 0.365). DISCUSSION: Corticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety. |
format | Online Article Text |
id | pubmed-5678641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56786412017-11-15 Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy Cai, Qingqing Xie, Xinfang Wang, Jinwei Shi, Sufang Liu, Lijun Chen, Yuqing Lv, Jicheng Zhang, Hong Kidney Int Rep Clinical Research INTRODUCTION: Few data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort. METHODS: A total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users. RESULTS: Of the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07–9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02–1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01–1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96–0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91–1.30; P = 0.365). DISCUSSION: Corticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety. Elsevier 2017-02-09 /pmc/articles/PMC5678641/ /pubmed/29142978 http://dx.doi.org/10.1016/j.ekir.2017.02.003 Text en © 2017 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Cai, Qingqing Xie, Xinfang Wang, Jinwei Shi, Sufang Liu, Lijun Chen, Yuqing Lv, Jicheng Zhang, Hong Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title_full | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title_fullStr | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title_full_unstemmed | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title_short | Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy |
title_sort | severe adverse effects associated with corticosteroid treatment in patients with iga nephropathy |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678641/ https://www.ncbi.nlm.nih.gov/pubmed/29142978 http://dx.doi.org/10.1016/j.ekir.2017.02.003 |
work_keys_str_mv | AT caiqingqing severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT xiexinfang severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT wangjinwei severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT shisufang severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT liulijun severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT chenyuqing severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT lvjicheng severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy AT zhanghong severeadverseeffectsassociatedwithcorticosteroidtreatmentinpatientswithiganephropathy |